NASDAQ: NSPRInspiremd Inc Stock
$1.92+0.07 (+3.78%)
Updated Apr 25, 2024
NSPR Price
$1.92
Fair Value Price
N/A
Market Cap
$44.92M
52 Week Low
$1.03
52 Week High
$3.85
P/E
-2.34x
P/B
1.14x
P/S
10.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.21M
Earnings
-$19.92M
Gross Margin
29.1%
Operating Margin
-319.92%
Profit Margin
-321%
Debt to Equity
0.21
Operating Cash Flow
-$16M
Beta
0.6
Next Earnings
May 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NSPR Overview
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NSPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NSPR is good value based on its book value relative to its share price (1.14x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
NSPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NSPR due diligence checks available for Premium users.
Be the first to know about important NSPR news, forecast changes, insider trades & much more!
NSPR News
Valuation
NSPR fair value
Fair Value of NSPR stock based on Discounted Cash Flow (DCF)
Price
$1.92
Fair Value
-$0.01
Undervalued by
20,331.50%
NSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NSPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.34x
Industry
29.73x
Market
40.97x
NSPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
3.71x
NSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NSPR's financial health
Profit margin
Revenue
$1.8M
Net Income
-$5.4M
Profit Margin
-306.9%
NSPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NSPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$47.6M
Liabilities
$8.1M
Debt to equity
0.21
NSPR's short-term assets ($44.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NSPR's short-term assets ($44.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NSPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
-$36.0k
Financing
$0.0
NSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NSPR vs Medical Device Stocks
Inspiremd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.